Apollomics Inc. (APLMW) — SEC Filings
Apollomics Inc. (APLMW) — 34 SEC filings. Latest: 6-K (Dec 22, 2025). Includes 27 6-K, 2 20-F, 2 SC 13D/A.
View Apollomics Inc. on SEC EDGAR
Overview
Apollomics Inc. (APLMW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 22, 2025: Apollomics Inc. filed a 6-K report on December 22, 2025, detailing financial information for the period ending June 30, 2025. The filing includes information on share capital, retained earnings, and reserves for share-based payments as of June 30, 2025, and comparative periods. It also mentions a se
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 30 neutral. The dominant filing sentiment for Apollomics Inc. is neutral.
Filing Type Overview
Apollomics Inc. (APLMW) has filed 27 6-K, 2 20-F, 2 SC 13D/A, 1 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of APLMW's 25 recent filings, 2 were flagged as high-risk, 15 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Yi-An Chu
- Chen-Huan Jan
- Hung-Wen (Howard) Chen
- Hong-Jung (Moses) Chen
- Yi-Kuei Chen
- Po-Jen Hsueh
- Dr. Guo-Liang Yu
- Dr. Matthew Plunkett
- Sanjeev Redkar, Ph.D.
- Peony Yu, M.D.
- Dr. Yu
- Matthew Plunkett, Ph.D.
Top Tags
sec-filing (6) · financials (2) · filing (2) · biotech (2) · oncology (2) · compliance (2) · private-placement (2) · drug-development (2) · regulatory-filing (2) · press-release (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Reporting Period | 2025 Q2 | Financial information is presented for the quarter ending June 30, 2025. |
| Product Candidates | 9 | Represents the breadth of Apollomics Inc.'s pipeline in oncology therapies. |
| Clinical Development Programs | 6 | Indicates the number of Apollomics Inc.'s product candidates currently undergoing clinical trials. |
| Board Members | 7 | Total number of directors after appointments |
| Minimum Bid Price | $1.00 | This is the threshold Apollomics Inc. needed to meet to regain compliance with Nasdaq listing rules. |
| Shares Represented | 40,155,852 | Represents the number of shares present at the Extraordinary General Meeting. |
| Outstanding Shares | 110,266,527 | Total number of shares issued by Apollomics Inc. |
| Extension Period | 180 | Additional days granted by Nasdaq to regain compliance with minimum bid price. |
| Filing Amendment | Amendment No. 5 | Indicates a modification to a previous filing. |
| Filing Date | May 22, 2024 | Date the amendment was submitted to the SEC. |
| Date of Change | May 20, 2024 | The date as of which the reported changes in beneficial ownership occurred. |
| Fiscal Year End | 2023-12-31 | Conformed Period of Report |
| SIC Code | 2834 | Standard Industrial Classification for Pharmaceutical Preparations |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Apollomics Inc. (APLMW)?
Apollomics Inc. has 34 recent SEC filings from Jan 2024 to Dec 2025, including 27 6-K, 2 20-F, 2 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of APLMW filings?
Across 34 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 30 neutral. The dominant sentiment is neutral.
Where can I find Apollomics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Apollomics Inc. (APLMW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Apollomics Inc.?
Financial highlights for Apollomics Inc. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for APLMW?
The investment thesis for APLMW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Apollomics Inc.?
Key executives identified across Apollomics Inc.'s filings include Yi-An Chu, Chen-Huan Jan, Hung-Wen (Howard) Chen, Hong-Jung (Moses) Chen, Yi-Kuei Chen and 7 others.
What are the main risk factors for Apollomics Inc. stock?
Of APLMW's 25 assessed filings, 2 were flagged high-risk, 15 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Apollomics Inc.?
Forward guidance and predictions for Apollomics Inc. are extracted from SEC filings as they are enriched.